长春高新(000661.SZ)：子公司GenSci145片境内生产药品注册临床试验申请获得批准

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for the clinical trial application of its drug GenSci145 tablets, which is a novel selective PI3Kα inhibitor intended for the treatment of locally advanced or metastatic solid tumors with PIK3CA mutations [1]. Group 1 - Jinsai Pharmaceutical has obtained the clinical trial approval for GenSci145 tablets [1] - GenSci145 is classified as a Class 1 innovative chemical drug [1] - The drug targets patients with PIK3CA mutations in solid tumors [1]